Persista Bio Inc.
PrivateLast Round
Pre Seed
Feb 5, 2026
Total Funding Raised
$2.4M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Persista Bio Inc. operates in Healthcare & Life Sciences and is based in Ithaca, New York. Its latest recorded funding round was an Accelerator round in October 2025.
Persista Bio Inc. is a biotechnology company that develops an oxygenated cell therapy platform designed to enable long-term, immunosuppression-free cell implants for the treatment of Type 1 diabetes and other chronic conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Persista Bio Inc. Comparables
Compare Persista Bio Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Encellin | 86% | |
| Procyon Technologies LLC | 86% | |
| iTolerance, Inc. | 80% |
For institutional investors. Book with your work email.
Persista Bio Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Pre Seed | Feb 5, 2026 | ||||
| Accelerator | Oct 1, 2025 | ||||
| Grant | Sep 23, 2025 | ||||
| Seed | Sep 23, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Persista Bio Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| National Institute of Diabetes and Digestive and Kidney Diseases | Grant |
| Kevin M. McGovern Family Center for Venture Development in the Life Sciences | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 16, 2026
Grew 38% QoQ from 8 to 11 employees.
- Apr 17, 2026
Monthly visitors grew 234% MoM, reaching 277.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 23, 2026
Persista Bio, Inc. is working on its first treatment for Type 1 diabetes as its O2Line™ cell implant system addresses oxygen supply, immunosuppression, and fibrosis challenges in cell-based therapies on Sep 23rd '26.
For institutional investors. Book with your work email.
Persista Bio Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Persista Bio Inc.'s valuation, stock price, and market status.
Is Persista Bio Inc. a public or private company?
Persista Bio Inc. is a private company.
What is the current stock price of Persista Bio Inc.?
Persista Bio Inc. is a private company, so its shares have no public market price. Caplight tracks Persista Bio Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Persista Bio Inc. worth (valuation)?
Valuation information for Persista Bio Inc. is not publicly available.
Can I buy Persista Bio Inc. stock?
Persista Bio Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Persista Bio Inc.'s last funding round?
Persista Bio Inc.'s most recent funding round was Pre Seed on February 5, 2026.
Who are the main investors in Persista Bio Inc.?
Key investors in Persista Bio Inc. include National Institute of Diabetes and Digestive and Kidney Diseases.
Will Persista Bio Inc. IPO soon?
No public IPO plans have been announced for Persista Bio Inc..
How can I track Persista Bio Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Persista Bio Inc.'s shares on secondary markets.